Linus Health, a specialist in digital detection of dementia, has expanded its focus to include the treatment of patients with the acquisition of Together Senior Health.
Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.
Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro
An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year